Suppr超能文献

欧洲肝脏研究协会与法国丙型肝炎最新指南:范式转变

European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift.

作者信息

Loustaud-Ratti Véronique, Debette-Gratien Marilyne, Carrier Paul

机构信息

Fédération d'Hépatologie, Service d'Hépato-gastroentérologie, CHU Limoges, Limoges 87042, France.

出版信息

World J Hepatol. 2018 Oct 27;10(10):639-644. doi: 10.4254/wjh.v10.i10.639.

Abstract

The latest Association Française pour l'Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients' management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the "reservoir" population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations.

摘要

法国肝脏研究协会(AFEF)和欧洲肝脏研究协会(EASL)的最新建议宣布了丙型肝炎病毒(HCV)感染患者管理模式的转变。AFEF的建议侧重于在不到十年的时间内,通过预防再次感染在国家层面消除HCV感染。这一目标包括通过增加筛查程序以及主要在注射吸毒者和移民这一“蓄水池”人群中提供泛基因型治疗,来简化患者管理途径。即使在有既往合并症患者的复杂管理途径中,AFEF也选择了治疗简化方案。EASL指南基于当前的技术水平,精确描述了所有可用的治疗选择,即使考虑到难治人群的流行病学演变,也没有区分简化和复杂途径。

相似文献

1
European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift.
World J Hepatol. 2018 Oct 27;10(10):639-644. doi: 10.4254/wjh.v10.i10.639.
3
Management of liver failure in general intensive care unit.
Anaesth Crit Care Pain Med. 2020 Feb;39(1):143-161. doi: 10.1016/j.accpm.2019.06.014. Epub 2019 Sep 13.
5
[Hepatitis C in a psychiatric setting: A forgotten reservoir?].
Encephale. 2021 Apr;47(2):181-184. doi: 10.1016/j.encep.2020.03.003. Epub 2020 May 27.
6
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey.
JHEP Rep. 2022 Sep;4(9):100531. doi: 10.1016/j.jhepr.2022.100531. Epub 2022 Jul 27.
8
Management of acute HCV infection in the era of direct-acting antiviral therapy.
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):412-424. doi: 10.1038/s41575-018-0026-5.
10
Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.
Aliment Pharmacol Ther. 2016 Jul;44(2):145-56. doi: 10.1111/apt.13673. Epub 2016 May 20.

本文引用的文献

2
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.
6
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
7
EASL Recommendations on Treatment of Hepatitis C 2016.
J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.
8
Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs.
J Subst Abuse Treat. 2016 Aug;67:44-9. doi: 10.1016/j.jsat.2016.04.001. Epub 2016 May 3.
9
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验